A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer
-
Published:2023-09
Issue:9
Volume:33
Page:1458-1463
-
ISSN:1048-891X
-
Container-title:International Journal of Gynecologic Cancer
-
language:en
-
Short-container-title:Int J Gynecol Cancer
Author:
Holloway Robert WORCID, Thaker Premal, Mendivil Alberto A, Ahmad SarfrazORCID, Al-Niaimi Ahmed N, Barter James, Beck Tiffany, Chambers Setsuko K, Coleman Robert L, Crafton Sarah M, Crane Erin, Eskander Ramez, Ghamande Sharad, Graybill Whitney, Herzog Thomas, Indermaur Megan Dr, John Veena S, Landrum Lisa, Lim Peter C, Lucci Joseph A, McHale Michael, Monk Bradley JORCID, Moore Kathleen Nadine, Morris Robert, O’Malley David M, Reid Thomas J, Richardson DebraORCID, Rose Peter G, Scalici Jennifer M, Silasi Dan-Arin, Tewari Krishnansu, Wang Edward W
Abstract
BackgroundTreatment options for patients with platinum-resistant/refractory ovarian cancers are limited and only marginally effective. The development of novel, more effective therapies addresses a critical unmet medical need. Olvimulogene nanivacirepvec (Olvi-Vec), with its strong immune modulating effect on the tumor microenvironment, may provide re-sensitization to platinum and clinically reverse platinum resistance or refractoriness in platinum-resistant/refractory ovarian cancer.Primary ObjectiveThe primary objective is to evaluate the efficacy of intra-peritoneal Olvi-Vec followed by platinum-based chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer.Study HypothesisThis phase III study investigates Olvi-Vec oncolytic immunotherapy followed by platinum-based chemotherapy and bevacizumab as an immunochemotherapy evaluating the hypothesis that such sequential combination therapy will prolong progression-free survival (PFS) and bring other clinical benefits compared with treatment with platinum-based chemotherapy and bevacizumab.Trial DesignThis is a multicenter, prospective, randomized, and active-controlled phase III trial. Patients will be randomized 2:1 into the experimental arm treated with Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab or the control arm treated with platinum-doublet chemotherapy and bevacizumab.Major Inclusion/Exclusion CriteriaEligible patients must have recurrent, platinum-resistant/refractory, non-resectable high-grade serous, endometrioid, or clear-cell ovarian, fallopian tube, or primary peritoneal cancer. Patients must have had ≥3 lines of prior chemotherapy.Primary EndpointThe primary endpoint is PFS in the intention-to-treat population.Sample SizeApproximately 186 patients (approximately 124 patients randomized to the experimental arm and 62 to the control arm) will be enrolled to capture 127 PFS events.Estimated Dates for Completing Accrual and Presenting ResultsExpected complete accrual in 2024 with presentation of primary endpoint results in 2025.Trial RegistrationNCT05281471.
Funder
Genelux Corporation, Westlake Village, CA
Subject
Obstetrics and Gynecology,Oncology
Reference30 articles.
1. Worschech A , Chen N , Yu YA , et al . Systemic treatment of xenografts with vaccinia virus GLV-1H68 reveals the immunologic facet of oncolytic therapy. BMC Genomics 2009;10:301. doi:10.1186/1471-2164-10-301 2. Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68 3. Ascierto ML , Worschech A , Yu Z , et al . Permissivity of the NCI-60 cancer cell lines to oncolytic vaccinia virus GLV-1H68. BMC Cancer 2011;11:451. doi:10.1186/1471-2407-11-451 4. Weibel S , Raab V , Yu YA , et al . Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. BMC Cancer 2011;11:68. doi:10.1186/1471-2407-11-68 5. Weibel S , Basse-Luesebrink TC , Hess M , et al . Imaging of intratumoral inflammation during oncolytic virotherapy of tumors by 19F-magnetic resonance imaging (MRI). PLoS One 2013;8:e56317. doi:10.1371/journal.pone.0056317
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|